Analysts Issue Forecasts for OPKO Health FY2028 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Investment analysts at Zacks Research issued their FY2028 earnings per share (EPS) estimates for shares of OPKO Health in a report released on Thursday, March 19th. Zacks Research analyst Team forecasts that the biotechnology company will earn ($0.16) per share for the year. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share.

OPK has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, January 22nd. Wall Street Zen cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Barrington Research lowered their target price on shares of OPKO Health from $2.25 to $1.50 and set an “outperform” rating on the stock in a report on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $2.03.

OPKO Health Price Performance

OPKO Health stock opened at $1.12 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 3.97 and a quick ratio of 3.52. The business has a 50 day simple moving average of $1.23 and a 200-day simple moving average of $1.34. OPKO Health has a 12 month low of $1.10 and a 12 month high of $1.83. The stock has a market capitalization of $850.16 million, a PE ratio of -3.73 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.03. The company had revenue of $148.50 million for the quarter, compared to the consensus estimate of $139.76 million. OPKO Health had a negative return on equity of 17.42% and a negative net margin of 37.19%.The company’s revenue was down 19.1% on a year-over-year basis. During the same period last year, the business posted $0.01 EPS.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Caprock Group LLC acquired a new stake in OPKO Health in the third quarter valued at $26,000. Zacks Investment Management acquired a new position in shares of OPKO Health during the 4th quarter worth $27,000. StoneX Group Inc. purchased a new position in shares of OPKO Health in the 4th quarter valued at about $27,000. Swiss Life Asset Management Ltd purchased a new position in shares of OPKO Health in the 3rd quarter valued at about $30,000. Finally, Savant Capital LLC purchased a new position in shares of OPKO Health in the 3rd quarter valued at about $33,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.